Cell and Gene Therapy Today—March 12, 2026

LucidQuest

8 hours ago

In Today’s Newsletter

Dive deeper

👁️ GenSight advances LUMEVOQ early access and REVISE enrollment [1] [EU • 09 Mar 2026]

https://www.biospace.com/press-releases/gensight-biologics-provides-updates-about-gs010-lumevoq-early-access-programs-and-the-ongoing-revise-study
Context: GS010/LUMEVOQ (GenSight Biologics; gene therapy for LHON caused by ND4 mutation) is in early access programs in France, Israel, and the US, with the REVISE dose-ranging study ongoing.
Key point: France approved initial named-patient AAC applications, a second patient was approved in Israel’s paid named-patient program, and a second US expanded-access patient cleared via individual IND.
Implication: May expand screening, initiation, and follow-up at scale.

🧬 Sangamo moves ST-920 rolling BLA forward in Fabry disease [2] [US • 09 Mar 2026]

https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-advances-rolling-submission-bla-us-fda-st
Context: ST-920, isaralgagene civaparvovec (Sangamo Therapeutics; gene therapy for adults with Fabry disease) is being pursued via accelerated approval.
Key point: Sangamo said it submitted the preclinical and clinical BLA modules, and said the FDA agreed the 52-week mean annualized eGFR slope from STAAR can support the accelerated approval endpoint.
Implication: May influence prescriber choice and payer reviews pending full data.

🦵 Atamyo reports early ATA-200 signals in LGMD-R5 [3] [EU • 09 Mar 2026]

https://www.biospace.com/press-releases/atamyo-therapeutics-presents-promising-results-in-the-first-patients-treated-with-its-ata-200-gene-therapy-in-the-clinical-trial-targeting-lgmd-r5-limb-girdle-muscular-dystrophy
Context: ATA-200 (Atamyo Therapeutics; AAV gene therapy carrying SGCG) is being studied in a Phase 1b/2 trial in children with LGMD-2C/R5 at the University of Florida.
Key point: In the first two patients with 9-month follow-up, Atamyo reported strong SGCG expression, lower CPK and transaminases, and encouraging functional signals; no serious side effects were reported across four treated patients.
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 uniQure’s AMT-130 faces regulatory and ethics debate before a possible Phase 3 [4] [US • 05 Mar 2026]

https://www.biospace.com/fda/uniqures-path-for-huntingtons-gene-therapy-clouded-by-ethical-questions-as-potential-phase-3-looms
Context: AMT-130 (uniQure; one-time gene therapy for Huntington’s disease) had previously been discussed as a possible accelerated path candidate based on Phase 1/2 data versus external controls.
Key point: BioSpace reported that the FDA appears to want a sham surgery-controlled Phase 3 trial, while investors, ethicists, and advocates debated whether 48-month data or another negotiated path could still support progress.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🏭 Lonza and Genetix expand ZYNTEGLO manufacturing capacity [5] [US • 09 Mar 2026]

https://www.lonza.com/news/2026-03-09-14-00
Context: Lonza and Genetix Biotherapeutics have worked together since 2013 on manufacturing for ZYNTEGLO (betibeglogene autotemcel), an FDA-approved gene therapy for transfusion-dependent beta-thalassemia.
Key point: The companies extended their commercial manufacturing agreement, with added capacity at Lonza’s Houston site to support growing demand and possible future Genetix therapies.
Implication: Signals pipeline investment and modality expansion.

👶 Astellas Gene Therapies starts cautious VALOR study in XLMTM [6] [US • 10 Mar 2026]

https://www.neurologylive.com/view/phase-1-2-valor-study-assess-asp2957-gene-therapy-infants-x-linked-myotubular-myopathy
Context: ASP2957 (Astellas Gene Therapies; MTM1-targeted AAV gene therapy) is in a first-in-human Phase 1/2 study in ventilator-dependent boys aged 3 years or younger with XLMTM.
Key point: VALOR plans dose escalation and expansion in up to nine patients, with sentinel dosing, 8-week staggering, immunosuppression, and intensive liver, cardiac, hematologic, and muscle monitoring.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 MiNK partners with C-Further on PRAME-targeted iNKT therapy for pediatric cancers [7] [10 Mar 2026]

https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-announces-collaboration-c-further-advance
Context: MiNK Therapeutics is developing an allogeneic iNKT platform, and C-Further is a pediatric oncology therapeutics consortium.
Key point: The collaboration will fund IND-enabling development of a PRAME-targeted TCR-engineered iNKT program for pediatric cancers, with MiNK as lead industry partner and University of Southampton investigators supporting candidate selection.
Implication: Signals pipeline investment and modality expansion.

❤️ Capricor gets new FDA date for Deramiocel review in Duchenne cardiomyopathy [8] [US • 10 Mar 2026]

https://www.capricor.com/investors/news-events/press-releases/detail/338/capricor-therapeutics-announces-establishment-of-new-pdufa
Context: Deramiocel (Capricor Therapeutics; investigational cell therapy) is under BLA review for Duchenne muscular dystrophy cardiomyopathy after a prior CRL in July 2025.
Key point: FDA lifted the earlier CRL, resumed review as a Class 2 resubmission, and set a PDUFA target action date of 22 Aug 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

👁️ FDA clears first-in-human SVT-001 study in familial drusen [9] [US • 07 Mar 2026]

https://www.ophthalmologytimes.com/view/fda-clears-phase-i-ii-trial-of-svt-001-cell-therapy-for-familial-drusen-associated-vision-loss
Context: SVT-001 (Sanaregen Vision Therapeutics; regenerative cell therapy) is entering Phase I/II testing in familial drusen, a rare inherited macular degeneration often linked to EFEMP1 variants.
Key point: FDA IND clearance allows first-in-human study initiation, with safety and preliminary retinal and visual function assessments planned; cell type, delivery route, and detailed protocol remain undisclosed.
Implication: May influence prescriber choice and payer reviews pending full data.

Why It Matters

Rare-disease gene and cell therapy programs continue to move on multiple fronts, clinical readouts, FDA review, access pathways, and manufacturing scale-up.
Neuromuscular diseases remain a major focus, with updates in LGMD-R5, XLMTM, Duchenne cardiomyopathy, and Huntington’s disease [3][4][6][8].
Ophthalmology is active across both gene therapy and regenerative cell therapy, spanning LHON and familial drusen [1][9].
Several items point to commercialization infrastructure, not just science, including early access revenues, rolling BLA progress, and expanded manufacturing capacity [1][2][5].
Regulatory design and ethics remain central, especially where invasive controls, accelerated approval endpoints, or limited early datasets shape the path forward [2][4][6][9].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 See the full Cell and Gene Therapy archive on our research hub page.

FAQ

What changed this week for ST-920 in Fabry disease?

Sangamo said its rolling BLA moved forward with the preclinical and clinical modules submitted to the FDA. The company also said the FDA agreed that 52-week mean annualized eGFR slope from STAAR can support the accelerated approval endpoint [2].

What do the early ATA-200 data show in LGMD-R5?

Atamyo reported early biomarker and functional signals in the first two treated patients, plus no serious side effects across four treated patients. These are early Phase 1b/2 data, so durability and broader efficacy still need more follow-up [3].

Why is AMT-130 in Huntington’s disease drawing ethical scrutiny?

BioSpace described a debate around whether a sham surgery-controlled Phase 3 should be required after earlier FDA interactions had suggested another path. The key issue is how much evidence is enough, balanced against the risks and feasibility of sham-controlled neurosurgical studies [4].

What is the significance of Capricor’s new PDUFA date for Deramiocel?

The FDA resumed review of the BLA and set 22 Aug 2026 as the target action date. That means the application is back under active review after the earlier CRL, which is a meaningful regulatory step for Duchenne cardiomyopathy [8].

What is notable about the VALOR trial in XLMTM?

The study design is deliberately cautious, with low starting doses, sentinel dosing, 8-week staggering, immunosuppression, and exclusion of prior hepatic dysfunction. That reflects lessons from prior MTM1 AAV experience and the safety sensitivity in this population [6].

What does FDA clearance of the SVT-001 trial mean for familial drusen?

It means Sanaregen can begin first-in-human Phase I/II testing in a disease with no approved disease-modifying therapies noted in the source. The current announcement supports a safety-first read, while mechanism and efficacy specifics remain limited in public materials [9].

Entities / Keywords

GenSight Biologics, GS010, LUMEVOQ, LHON, Leber Hereditary Optic Neuropathy, ND4, REVISE, AAC, expanded access
Sangamo Therapeutics, ST-920, isaralgagene civaparvovec, Fabry disease, STAAR, eGFR, rolling BLA, PMA
Atamyo Therapeutics, ATA-200, LGMD-R5, LGMD-2C, gamma-sarcoglycanopathy, SGCG, AAV gene therapy
uniQure, AMT-130, Huntington’s disease, sham surgery-controlled Phase 3, Type B meeting
Lonza, Genetix Biotherapeutics, ZYNTEGLO, betibeglogene autotemcel, transfusion-dependent beta-thalassemia, commercial manufacturing
Astellas Gene Therapies, ASP2957, VALOR, XLMTM, X-linked myotubular myopathy, MTM1, ASPIRO
MiNK Therapeutics, C-Further, PRAME, TCR-engineered iNKT, pediatric cancers, allogeneic cell therapy
Capricor Therapeutics, Deramiocel, Duchenne muscular dystrophy, DMD cardiomyopathy, HOPE-3, PDUFA
Sanaregen Vision Therapeutics, SVT-001, familial drusen, EFEMP1, Doyne honeycomb retinal dystrophy, Malattia Leventinese